Serum biomarker panel for disease severity and prognosis in patients with COVID ‐19
Journal of Clinical Laboratory Analysis · 2023
DOI: 10.1002/jcla.24831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Jing Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Doctor Start-Up Fund, The First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars.
Abstract (Originalsprache)
Background
Coronavirus disease‐2019 (COVID‐19) has become a worldwide emergency and has had a severe impact on human health. Inflammatory factors have the potential to either enhance the efficiency of host immune responses or damage the host organs with immune overreaction in COVID‐19. Therefore, there is an urgent need to investigate the functions of inflammatory factors and serum markers that participate in disease progression.
Methods
In total, 54 COVID‐19 patients were enrolled in this study. Disease severity was evaluated by clinical evaluation, laboratory tests, and computed tomography (CT) scans. Data were collected at: admission, 3–5 days after admission, when severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA detection became negative, and composite endpoint.
Results
We found that the positive rate in sputum was three times higher than that in throat swabs. Higher levels of C‐reactive protein (CRP), lactate dehydrogenase (LDH), D‐dimer (D‐D), interleukin‐6 (IL‐6) and neutrophil‐to‐lymphocyte ratio (NLR) or lower lymphocyte counts suggested more severe disease, and the levels of cytokines and serum markers were intrinsically correlated with disease progression. When SARS‐CoV‐2 RNA detection became negative, the receiver operating characteristic (ROC) curve demonstrated that LDH had the highest sensitivity independently, and four indicators (NLR, CRP, LDH, and D‐D) when combined had the highest sensitivity in distinguishing critically ill patients from mild ones.
Conclusions
Monitoring dynamic changes in NLR, CRP, LDH, IL‐6, and D‐D levels, combined with CT imaging and viral RNA detection in sputum, could aid in severity evaluation and prognosis prediction and facilitate COVID‐19 treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
- Department of Clinical Medical, Bengbu Medical College, Bengbu, China.
- Department of Radiology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
ORCID-Profile: Yanqing Yang
Förderung
- Doctor Start-Up Fund
- The First Affiliated Hospital of Bengbu Medical College Science Fund for Outstanding Young Scholars
Zitieren
APA
Li, J., Tang, M., Liu, D., Xie, Z., Wang, F., & Yang, Y. (2023). Serum biomarker panel for disease severity and prognosis in patients with COVID ‐19. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24831
Vancouver
Li J, Tang M, Liu D, Xie Z, Wang F, Yang Y. Serum biomarker panel for disease severity and prognosis in patients with COVID ‐19. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24831
BibTeX
@article{Li2023,
author = {Li, Jing and Tang, Mingyang and Liu, Didi and Xie, Zongyu and Wang, Fengchao and Yang, Yanqing},
title = {Serum biomarker panel for disease severity and prognosis in patients with COVID ‐19},
journal = {Journal of Clinical Laboratory Analysis},
year = {2023},
doi = {10.1002/jcla.24831}
}
EUVIMED